Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of five systematic review(s)/meta-analysis(es). ^[1-5]
• Gallium 68 gozetotide (gozetotide, also known as PSMA-11) demonstrated high diagnostic accuracy for detecting and staging primary prostate cancer. Sensitivity and specificity were 0.87 (95% CI (confidence interval): 0.80-0.92) and 0.80 (95% CI: 0.69-0.89), respectively, compared to mpMRI. It also showed higher sensitivity for pelvic lymph node staging with a sensitivity of 0.71 (95% CI: 0.48-0.86) versus mpMRI's 0.40 (95% CI: 0.16-0.71).
• In staging, gallium 68 gozetotide PET (positron emission tomography)/MRI (magnetic resonance imaging) showed slightly higher diagnostic accuracy for lymph node metastasis (LNM) compared to PET/CT, with a lnDOR of 4.73 (95% CI: 2.93-6.52) for PET/MRI vs. 2.42 (95% CI: 2.07-2.78) for PET/CT, indicating its effectiveness in detailed prostate cancer staging.
• There is no safety information available in the reviewed studies.
• Specific populations studied with gallium 68 gozetotide (PSMA-11) include patients with primary prostate cancer and those with biochemically recurrent prostate cancer (P = 0.58 (BCR)). In both groups, gallium 68 gozetotide (PSMA-11) PET/CT demonstrated high diagnostic accuracy, showing comparable effectiveness to mpMRI in primary prostate cancer detection and superior sensitivity in pelvic lymph node staging. PET/MRI showed slightly higher accuracy than PET/CT for lymph node metastasis (LNM) detection.